+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Intratumoral Cancer Therapy Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 172 Pages
  • February 2022
  • Region: Global
  • Renub Research
  • ID: 5546204
Global Intratumoral Cancer Therapy Market will reach US$ 212.92 Billion by 2027. As per Globocan statistics Worldwide, cancer is the highest cause of death; with 19,292,789 new cancer cases were diagnosed and around 9,958,133 cancer death happened in the year 2020. Nevertheless, over the past years, the treatment paradigm of cancer has transformed with several therapies such as radiation therapies, chemotherapies, and immunotherapies available to treat cancer. Correspondingly, intratumoral immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. This therapy is preferable to the old technique because it provides long-term cancer protection, has fewer side effects, and treats a broader range of cancer.

Impact of COVID-19 on Intratumoral Cancer Therapy Industry:


COVID-19 had a mixed impact on the intratumoral cancer therapy industry. Due to the lockdown restrictions and travel ban, it was difficult for the patients to get the therapy done. In the COVID- 19, there is a high chance for cancer patients to get infected because COVID 19 affects the patient's immune systems. However, continuous cancer intratumoral treatment processes for cancer patients are mandatory, and it enhances their immune system's ability to fight against COVID. Intratumoral therapy is a cancer treatment that boosts the human immune system to fight against cancer cells. Further, cancer patients require regular monitoring of the conditions, resulting in industry growth.

Although many factors propel the growth of the global intratumoral cancer therapy market, such as an increase in healthcare expenditure, a surge in access to medical insurance, a rise in the incidence of cancer, and a rise in technological advancements in cancer treatment therapies. According to this report the Worldwide Intratumoral Cancer Therapy Market Size was US$ 111.41 Billion in 2021.

Global Intratumoral Cancer Therapy Industry will grow at a CAGR of 11.4% from 2021-2027


Based on technology, the intratumoral cancer therapy industry includes Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others. The monoclonal antibody technology has the most significant growth in the previous year, owing to a surge in monoclonal antibodies for cancer immunotherapy. They exhibit different properties where the immune technique can be modulated, and thus they can activate or inhibit the molecules targeted on the immune system. Additionally, monoclonal antibodies also generate the antitumor immune response. There are various monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies.

In terms of application, cancer intratumoral therapy is used to treat various cancer applications like Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others. Lungs cancer had the most consequential market. Owing to the high incidence of lung cancer globally and the surge in the awareness program regarding the need for early lung cancer therapeutics. The U.S. food and drug administration has authorized Tabrecta (Capmatinib) to regale non-small cell lung cancer in 2020.

North America holds a Considerable Cancer Intratumoral Therapy Market Worldwide


Geographically, North America held a considerable global cancer intratumoral therapy market. Rising accessibility to current therapy and increasing cancer disease incidence, combined with a growing senior population, lead to regional market development. Recently, U.S. food and administration has supported 32 various immunotherapies to treat 20 cancer diseases, including immunomodulators, cell-based immunotherapies, BCG vaccines, targeted therapies, and oncotic viruses.

The Asia Pacific is to experience the fastest growth owing to a rise in healthcare expenditure, the surge in per capita income, and improvement in healthcare infrastructure. Countries like China and Japan are introducing new and sophisticated immunotherapy medications. These countries have clinical trials for new drug molecules, alternative treatments, and FDA approval.

Key Market Players:


The major players operating in the global intratumoral cancer therapy market include Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc.

This research report titled “Intratumoral Cancer Therapy Market, Global Forecast, by Application (Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others), Technology Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), End Users (Hospital, Cancer Research Centres, Clinical), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc)” provides a complete analysis of Global Intratumoral Cancer Therapy Industry


Application - Market has been covered from 7 viewpoints


  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

Technology Type - Market has been covered from 6 viewpoints


  • Monoclonal Antibodies
  • Vaccines
  • Checkpoint Inhibitors
  • Cell Therapies
  • Immune System Modulators
  • Adoptive Cell Transfer
  • Cytokines
  • Others

End Users - Market has been covered from 3 viewpoints


  • Hospital
  • Cancer Research Centres
  • Clinical

Regions - Market has been covered from 5 viewpoints


  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Company Insights:


  • Overview
  • Initiatives & Strategy
  • Revenue

Companies Covered in the Report:


  • Amgen Inc
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novarts AG
  • Johnson & Johnson
  • Eli Lily Company
  • F. Hoffmann-la Roche Ltd
  • Seattle Genetics Inc
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Drivers
4.2 Restraints
5. Global Intratumoral Cancer Therapy Market
6. Market Share Analysis - Global Intratumoral Cancer Therapy Market
6.1 By Application
6.2 Technology Type
6.3 By End User
6.4 By Regions
7. Application - Global Intratumoral Cancer Therapy Market
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Melanoma
7.5 Prostate Cancer
7.6 Head & Neck Cancer
7.7 Others
8. Technology Type - Global Intratumoral Cancer Therapy Market
8.1 Monoclonal Antibodies
8.2 Vaccines
8.3 Checkpoint Inhibitors
8.4 Cell Therapies
8.5 Immune System Modulators
8.6 Adoptive Cell Transfer
8.7 Cytokines
8.8 Others
9. End Users - Global Intratumoral Cancer Therapy Market
9.1 Hospital
9.2 Cancer Research Centres
9.3 Clinica
10. Regions - Global Intratumoral Cancer Therapy Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa
11. Porters Five Forces
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12. Company Analysis - Global Intratumoral Cancer Therapy Market
12.1 Amgen Inc.
12.1.1 Overview
12.1.2 Initiatives & Strategy
12.1.3 Revenue
12.2 AstraZeneca
12.2.1 Overview
12.2.2 Initiatives & Strategy
12.2.3 Revenue
12.3 Bayer AG
12.3.1 Overview
12.3.2 Initiatives & Strategy
12.3.3 Revenue
12.4 Bristol-Myers Squibb Comapny
12.4.1 Overview
12.4.2 Initiatives & Strategy
12.4.3 Revenue
12.5 Pfizer Inc
12.5.1 Overview
12.5.2 Initiatives & Strategy
12.5.3 Revenue
12.6 Novarts AG
12.6.1 Overview
12.6.2 Initiatives & Strategy
12.6.3 Revenue
12.7 Johnson & Johnson
12.7.1 Overview
12.7.2 Initiatives & Strategy
12.7.3 Revenue
12.8 Eli Lily Comapny
12.8.1 Overview
12.8.2 Initiatives & Strategy
12.8.3 Revenue
12.9 F. Hoffmann-la Roche Ltd
12.9.1 Overview
12.9.2 Initiatives & Strategy
12.9.3 Revenue
12.10 Seattle Genetics Inc
12.10.1 Overview
12.10.2 Initiatives & Strategy
12.10.3 Revenue
List of Figures
Figure 01: Global - Intratumoral Cancer Therapy Market (Billion US$), 2017 - 2021
Figure 02: Global - Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 - 2027
Figure 03: Application - Lung Cancer Market (Billion US$), 2017 - 2021
Figure 04: Application - Forecast for Lung Cancer Market (Billion US$), 2022 - 2027
Figure 05: Application - Breast Cancer Market (Billion US$), 2017 - 2021
Figure 06: Application - Forecast for Breast Cancer Market (Billion US$), 2022 - 2027
Figure 07: Application - Colorectal Cancer Market (Billion US$), 2017 - 2021
Figure 08: Application - Forecast for Colorectal Cancer Market (Billion US$), 2022 - 2027
Figure 09: Application - Melanoma Market (Billion US$), 2017 - 2021
Figure 10: Application - Forecast for Melanoma Market (Billion US$), 2022 - 2027
Figure 11: Application - Prostate Cancer Market (Billion US$), 2017 - 2021
Figure 12: Application - Forecast for Prostate Cancer Market (Billion US$), 2022 - 2027
Figure 13: Application - Head & Neck Cancer Market (Billion US$), 2017 - 2021
Figure 14: Application - Forecast for Head & Neck Cancer Market (Billion US$), 2022 - 2027
Figure 15: Application - Others Market (Billion US$), 2017 - 2021
Figure 16: Application - Forecast for Others Market (Billion US$), 2022 - 2027
Figure 17: Technology Type - Monoclonal Antibodies Market (Billion US$), 2017 - 2021
Figure 18: Technology Type - Forecast for Monoclonal Antibodies Market (Billion US$), 2022 - 2027
Figure 19: Technology Type - Vaccines Market (Billion US$), 2017 - 2021
Figure 20: Technology Type - Forecast for Vaccines Market (Billion US$), 2022 - 2027
Figure 21: Technology Type - Checkpoint Inhibitors Market (Billion US$), 2017 - 2021
Figure 22: Technology Type - Forecast for Checkpoint Inhibitors Market (Billion US$), 2022 - 2027
Figure 23: Technology Type - Cell Therapies Market (Billion US$), 2017 - 2021
Figure 24: Technology Type - Forecast for Cell Therapies Market (Billion US$), 2022 - 2027
Figure 25: Technology Type - Immune System Modulators Market (Billion US$), 2017 - 2021
Figure 26: Technology Type - Forecast for Immune System Modulators Market (Billion US$), 2022 - 2027
Figure 27: Technology Type - Adoptive Cell Transfer Market (Billion US$), 2017 - 2021
Figure 28: Technology Type - Forecast for Adoptive Cell Transfer Market (Billion US$), 2022 - 2027
Figure 29: Technology Type - Cytokines Market (Billion US$), 2017 - 2021
Figure 30: Technology Type - Forecast for Cytokines Market (Billion US$), 2022 - 2027
Figure 31: Technology Type - Others Market (Billion US$), 2017 - 2021
Figure 32: Technology Type - Forecast for Others Market (Billion US$), 2022 - 2027
Figure 33: End User - Hospital Market (Billion US$), 2017 - 2021
Figure 34: End User - Forecast for Hospital Market (Billion US$), 2022 - 2027
Figure 35: End User - Cancer Research Centres Market (Billion US$), 2017 - 2021
Figure 36: End User - Forecast for Cancer Research Centres Market (Billion US$), 2022 - 2027
Figure 37: End User - Clinical Market (Million US$), 2017 - 2021
Figure 38: End User - Forecast for Clinical Market (Million US$), 2022 - 2027
Figure 39: North America - Intratumoral Cancer Therapy Market (Billion US$), 2017 - 2021
Figure 40: North America - Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 - 2027
Figure 41: Europe - Intratumoral Cancer Therapy Market (Million US$), 2017 - 2021
Figure 42: Europe - Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 - 2027
Figure 43: Asia Pacific - Intratumoral Cancer Therapy Market (Billion US$), 2017 - 2021
Figure 44: Asia Pacific - Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 - 2027
Figure 45: Latin America - Intratumoral Cancer Therapy Market (Billion US$), 2017 - 2021
Figure 46: Latin America - Forecast for Intratumoral Cancer Therapy Market (Billion US$), 2022 - 2027
Figure 47: Middle East & Africa - Intratumoral Cancer Therapy Market (Million US$), 2017 - 2021
Figure 48: Middle East & Africa - Forecast for Intratumoral Cancer Therapy Market (Million US$), 2022 - 2027
Figure 49: Amgen Inc. - Global Revenue (Million US$), 2017 - 2021
Figure 50: Amgen Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 51: AstraZeneca - Global Revenue (Million US$), 2017 - 2021
Figure 52: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 53: Bayer AG - Global Revenue (Million US$), 2017 - 2021
Figure 54: Bayer AG - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 55: Bristol-Myers Squibb Comapny - Global Revenue (Million US$), 2017 - 2021
Figure 56: Bristol-Myers Squibb Comapny - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 57: Pfizer Inc - Global Revenue (Million US$), 2017 - 2021
Figure 58: Pfizer Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 59: Novarts AG - Global Revenue (Million US$), 2017 - 2021
Figure 60: Novarts AG - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 61: Johnson & Johnson - Global Revenue (Million US$), 2017 - 2021
Figure 62: Johnson & Johnson - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 63: Eli Lily Comapny - Global Revenue (Million US$), 2017 - 2021
Figure 64: Eli Lily Comapny - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 65: F. Hoffmann-la Roche Ltd - Global Revenue (Million US$), 2017 - 2021
Figure 66: F. Hoffmann-la Roche Ltd - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 67: Seattle Genetics Inc - Global Revenue (Million US$), 2017 - 2021
Figure 68: Seattle Genetics Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
List of Tables
Table 01: Global - Intratumoral Cancer Therapy Market Share by Application (Percent), 2017 - 2021
Table 02: Global - Forecast for Intratumoral Cancer Therapy Market Share by Application (Percent), 2022 - 2027
Table 03: Global - Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2017 - 2021
Table 04: Global - Forecast for Intratumoral Cancer Therapy Market Share by Technology Type (Percent), 2022 - 2027
Table 05: Global - Intratumoral Cancer Therapy Market Share by End User (Percent), 2017 - 2021
Table 06: Global - Forecast for Intratumoral Cancer Therapy Market Share by End User (Percent), 2022 - 2027
Table 07: Global - Intratumoral Cancer Therapy Market Share by Region (Percent), 2017 - 2021
Table 08: Global - Forecast for Intratumoral Cancer Therapy Market Share by Region (Percent), 2022 - 2027

Companies Mentioned

  • Amgen Inc
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novarts AG
  • Johnson & Johnson
  • Eli Lily Company
  • F. Hoffmann-la Roche Ltd
  • Seattle Genetics Inc

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information